Key Event Components

Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
A complete list of all KECs is available in TSV format on the Downloads Page.

Showing 751 to 775 of 1152 KECs

ID	Action	Process	Object	Associated Key Events (KEs)


448	increased	Microvesicular hepatic steatosis (HP:0001414)		838: Induction, Microvesicular fat
4	decreased	mitochondrial electron transport, NADH to ubiquinone (GO:0006120)	NADH-ubiquinone oxidoreductase chain 1 (PR:000031316)	888: Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I)
92	decreased	mitochondrial transport (GO:0006839)	cholesterol (CHEBI:16113)	447: Reduction, Cholesterol transport in mitochondria
177	functional change	mitochondrion disassembly (GO:0061726)	mitochondrion (GO:0005739)	None
955	occurrence	modulation by virus of host immune response (GO:0075528)		2180: Immune mechanisms antagonized by viral proteins
16	increased	mortality (MESH:D009026)		4 Events 351: Increased Mortality 350: Increase, Mortality 1135: Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction 947: Increase, Early Life Stage Mortality
762	increased	mRNA transcription (GO:0009299)	ssRNA viral genome (GO:0019024)	1847: Increased SARS-CoV-2 production
770	disrupted	mRNA transcription (GO:0009299)	angiotensin-converting enzyme 2 (PR:000003622)	None
777	decreased	mRNA transcription (GO:0009299)	aromatase (PR:000006100)	408: reduction in ovarian granulosa cells, Aromatase (Cyp19a1)
812	increased	mRNA transcription (GO:0009299)	angiotensin-converting enzyme 2 (human) (PR:Q9BYF1)	None
815	increased	mRNA transcription (GO:0009299)	angiotensin-converting enzyme 2 (PR:000003622)	1854: Dysregulation, ACE2 expression and activity
1125	decreased	mRNA transcription (GO:0009299)	undifferentiated genital tubercle (UBERON:0005876)	None
794	decreased	mucociliary clearance trait (VT:0001947)		1909: Mucociliary Clearance, Decreased
805	increased	mucus secretion (GO:0070254)	lung goblet cell (CL:1000143)	1251: Chronic, Mucus hypersecretion
482	occurrence	mucus secretion (GO:0070254)		None
136	abnormal	multi-organism reproductive process (GO:0044703)		253: N/A, Reproductive failure
15	increased	muscle contraction (GO:0006936)		2 Events 993: Decrease, Abdominal muscle contraction 601: Overactivation, muscle contraction
337	increased	musculoskeletal movement (GO:0050881)	valve (UBERON:0003978)	1142: Increased, valve movement
73	increased	mutation (MESH:D009154)	deoxyribonucleic acid (CHEBI:16991)	3 Events 185: Increase, Mutations 336: Increase, Heritable mutations in offspring 876: Increase, Mutations in Critical Genes
226	increased	mutation (MESH:D009154)	cellular tumor antigen p53 (PR:000003035)	376: Increased, Induced Mutations in Critical Genes
861	increased	mutation (MESH:D009154)		1669: Increased, DNA damage and mutation
5	decreased	NADH dehydrogenase (ubiquinone) activity (GO:0008137)	NADH-ubiquinone oxidoreductase chain 1 (PR:000031316)	887: Inhibition, NADH-ubiquinone oxidoreductase (complex I)
461	increased	necrotic cell death (GO:0070265)		2 Events 868: Increase, Tissue Degeneration, Necrosis & Atrophy 1263: Necrosis
781	decreased	negative regulation of blood coagulation (GO:0030195)		1866: Fibrinolysis, decreased
745	decreased	negative regulation of DNA binding (GO:0043392)	protein-DNA complex (GO:0032993)	1717: Suppression of STAT5 binding to cytokine gene promoters